Veronica J. Alexander
About
Veronica J. Alexander is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery.
According to data from OpenAlex, Veronica J. Alexander has authored 44 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Cardiology and Cardiovascular Medicine, 21 papers in Endocrinology, Diabetes and Metabolism and 19 papers in Surgery. Recurrent topics in Veronica J. Alexander's work include Lipid metabolism and disorders (31 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (17 papers) and Lipoproteins and Cardiovascular Health (14 papers). Veronica J. Alexander is often cited by papers focused on Lipid metabolism and disorders (31 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (17 papers) and Lipoproteins and Cardiovascular Health (14 papers). Veronica J. Alexander collaborates with scholars based in United States, Canada and Netherlands. Veronica J. Alexander's co-authors include Joseph L. Witztum, Richard S. Geary, Steven G. Hughes, Daniel Gaudet, Brenda F. Baker, Sotirios Tsimikas, Mark J. Graham, W. S. Singleton, Rosanne M. Crooke and Louis O’Dea and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and Circulation Research.
In The Last Decade
Veronica J. Alexander
40 papers receiving 2.8k citations
Hit Papers
Peers
Veronica J. Alexander
Nicholas J. Viney United States
Poulabi Banerjee United States
Calvin Yeang United States
Eunju Hurh United States
E H Ludwig United States
Alexis Baass Canada
Mathilde Varret France
Marianne Abifadel France
David Rhainds Canada
JoAnn Flaim United States
Citations per year, relative to Veronica J. Alexander Veronica J. Alexander (= 1×)
peers
Nicholas J. Viney
Countries citing papers authored by Veronica J. Alexander
Since
Specialization
Citations
This map shows the geographic impact of Veronica J. Alexander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica J. Alexander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica J. Alexander more than expected).
Fields of papers citing papers by Veronica J. Alexander
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Veronica J. Alexander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica J. Alexander. The network helps show where Veronica J. Alexander may publish in the future.
Co-authorship network of co-authors of Veronica J. Alexander
This figure shows the co-authorship network connecting the top 25 collaborators of Veronica J. Alexander. A scholar is included among the top collaborators of Veronica J. Alexander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica J. Alexander. Veronica J. Alexander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Brown, Alan S., Philippe Moulin, Veronica J. Alexander, et al.. (2025). Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study. Journal of clinical lipidology. 19(5). 1451–1456.
2.
Bajaj, Archna, Elif A Oral, Alan S. Brown, et al.. (2025). Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide. American Journal of Preventive Cardiology. 24. 101352–101352.
3.
Kessler, Asia Sikora, T. Michelle Brown, Emily Bratlee‐Whitaker, et al.. (2025). Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participants. Journal of clinical lipidology. 19(5). 1243–1255.
4.
Alexander, Veronica J., Marcello Arca, Jean Bergeron, et al.. (2025). Prevalence, baseline characteristics, and reclassification of indeterminate genetic results in patients eligible for the Balance trial with olezarsen. Journal of clinical lipidology. 19(3). e72–e72.
5.
Kessler, Asia Sikora, Ewa Karwatowska‐Prokopczuk, Veronica J. Alexander, et al.. (2025). Olezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome. Journal of clinical lipidology. 20(2). 299–309.
6.
Yang, Xiaohong, Veronica J. Alexander, Shuting Xia, & Sotirios Tsimikas. (2025). Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome. Atherosclerosis. 408. 120462–120462.
7.
Marston, Nicholas, Brian A. Bergmark, Veronica J. Alexander, et al.. (2025). Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. American Heart Journal. 286. 125–135.
8.
Bergmark, Brian A., Nicholas Marston, Thomas A Prohaska, et al.. (2025). Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial. American Heart Journal. 286. 116–124.
9.
Brown, T. Michelle, Emily Bratlee‐Whitaker, Marcello Arca, et al.. (2024). Patient Experience with Familial Chylomicronemia Syndrome before and after Olezarsen Treatment: Qualitative Interviews with Clinical Trial Participants. Journal of clinical lipidology. 18(4). e568–e569.
10.
Tsimikas, Sotirios, Henry N. Ginsberg, Veronica J. Alexander, et al.. (2024). Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteria. Journal of clinical lipidology. 19(3). 422–431.
11.
Prohaska, Thomas A, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, et al.. (2023). APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. Journal of clinical lipidology. 17(3). 406–411.
12.
Oral, Elif A, Abhimanyu Garg, Joseph A. Tami, et al.. (2022). Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study. Journal of clinical lipidology. 16(6). 833–849.
13.
Watts, Lynnetta M., Ewa Karwatowska‐Prokopczuk, Eunju Hurh, et al.. (2020). Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers. Nucleic Acid Therapeutics. 30(4). 198–206.
14.
O’Dea, Louis, James E. MacDougall, Veronica J. Alexander, et al.. (2019). Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society. 3(12). 2397–2410.
15.
Ramms, Bastian, Chelsea Nora, Ariane Pessentheiner, et al.. (2019). ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. Journal of Lipid Research. 60(8). 1379–1395.
16.
Alexander, Veronica J., Shuting Xia, Eunju Hurh, et al.. (2019). N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. European Heart Journal. 40(33). 2785–2796.
17.
Alexander, Veronica J., Andrés Digenio, Shuting Xia, et al.. (2018). INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES. Journal of the American College of Cardiology. 71(11). A1724–A1724.
18.
Blom, Dirk, Louis O’Dea, Andrés Digenio, et al.. (2018). Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. Journal of clinical lipidology. 12(5). 1234–1243.e5.
19.
Yang, Xiaohong, Sang Rok Lee, Yun-Seok Choi, et al.. (2016). Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. Journal of Lipid Research. 57(4). 706–713.
20.
Gaudet, Daniel, Diane Brisson, Karine Tremblay, et al.. (2014). Targeting APOC3 in the Familial Chylomicronemia Syndrome. New England Journal of Medicine. 371(23). 2200–2206.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nicholas J. Viney Breakdown of academic impact, for papers by Poulabi Banerjee Breakdown of academic impact, for papers by Calvin Yeang Breakdown of academic impact, for papers by Eunju Hurh Breakdown of academic impact, for papers by E H Ludwig Breakdown of academic impact, for papers by Alexis Baass Breakdown of academic impact, for papers by Mathilde Varret Breakdown of academic impact, for papers by Marianne Abifadel Breakdown of academic impact, for papers by David Rhainds Breakdown of academic impact, for papers by JoAnn Flaim